Tucatinib is an oral, small-molecule tyrosine kinase inhibitor (TKI) that selectively targets the HER2 (human epidermal growth factor receptor 2) signaling pathway. It is used in combination therapy for the treatment of HER2-positive breast cancer, including cases with brain metastases. Tucatinib offers a high degree of selectivity for HER2 over EGFR, minimizing off-target effects such as skin rash and diarrhea commonly associated with other HER2 inhibitors.
It is marketed under the brand name Tukysa® and is administered orally in tablet form.
Therapeutic indications include:
• HER2-positive metastatic breast cancer (in combination with trastuzumab and capecitabine)
• HER2-positive breast cancer with brain metastases
• Investigational use in other HER2-positive solid tumors
Impurities in tucatinib primarily arise from its multi-step chemical synthesis, which includes heterocycle formation, amide bond coupling, and selective substitution reactions. Given the complexity and targeted nature of the molecule, impurity profiling is critical, especially for potential genotoxic impurities (PGIs). All impurities are controlled under ICH Q3A/B and, where applicable, ICH M7 guidelines.
Process-Related Impurities
• Unreacted starting materials such as substituted quinazoline or benzamide derivatives
• Intermediates or side-products from selective halogenation or amination
• Residual solvents like DMF, acetonitrile, or dichloromethane
• By-products from coupling agents (e.g., HATU, EDC)
• Regioisomeric or stereoisomeric impurities
Degradation Impurities
• Hydrolysis of amide or ether linkages under stress conditions
• Oxidation of aromatic rings or methoxy substituents
• Photodegradation or rearrangement under light exposure
• N-oxide formation at tertiary nitrogen centers
Elemental Impurities
• Trace metals such as palladium, copper, or iron from catalysts and manufacturing equipment
• Must comply with ICH Q3D limits for oral solid dosage forms
Analytical Techniques for Impurity Detection
Tucatinib is used to treat HER2-positive metastatic breast cancer, including in patients with brain metastases, in combination with trastuzumab and capecitabine.
It selectively inhibits HER2 tyrosine kinase, blocking downstream signaling pathways that promote cancer cell growth and survival.
Yes. Tucatinib is a highly selective HER2-targeted therapy, offering efficacy with reduced EGFR-related toxicities compared to earlier-generation HER2 inhibitors.
Store at room temperature (20–25°C), in a dry place, protected from moisture and light. Keep tablets in the original container.
